192 related articles for article (PubMed ID: 36206503)
21. Boosting with Multiple Doses of mRNA Vaccine after Priming with Two Doses of Protein Subunit Vaccine MVC-COV1901 Elicited Robust Humoral and Cellular Immune Responses against Emerging SARS-CoV-2 Variants.
Chiu CH; Chang YH; Tao CW; Chang FY; Chiu KC; Chang TW; Yen LC
Microbiol Spectr; 2022 Oct; 10(5):e0060922. PubMed ID: 36005765
[TBL] [Abstract][Full Text] [Related]
22. Humoral and cellular immunogenicity of SARS-CoV-2 vaccines in chronic lymphocytic leukemia: a prospective cohort study.
Haydu JE; Maron JS; Redd RA; Gallagher KME; Fischinger S; Barnes JA; Hochberg EP; Johnson PC; Takvorian RW; Katsis K; Portman D; Ruiters J; Sechio S; Devlin M; Regan C; Blumenthal KG; Banerji A; Judd AD; Scorsune KJ; McGree BM; Sherburne MM; Lynch JM; Weitzman JI; Lei M; Kotton CN; Dighe AS; Maus MV; Alter G; Abramson JS; Soumerai JD
Blood Adv; 2022 Mar; 6(6):1671-1683. PubMed ID: 35073571
[TBL] [Abstract][Full Text] [Related]
23. Effects of the BTN162b2 mRNA COVID-19 vaccine in humoral and cellular immunity in patients with chronic lymphocytic leukemia.
Fiorcari S; Atene CG; Maffei R; Mesini N; Debbia G; Colasante C; Pozzi S; Barbieri E; Maccaferri M; Leonardi G; Potenza L; Luppi M; Marasca R
Hematol Oncol; 2023 Feb; 41(1):120-127. PubMed ID: 36156278
[TBL] [Abstract][Full Text] [Related]
24. Seroconversion panels demonstrate anti-SARS-CoV-2 antibody development after administration of the mRNA-1273 vaccine.
Belda F; Mora O; Lopez Martinez M; Torres N; Vivanco A; Christie R; Crowley M
Vaccine; 2022 May; 40(22):2993-2998. PubMed ID: 35443917
[TBL] [Abstract][Full Text] [Related]
25. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
Zhang Y; Zeng G; Pan H; Li C; Hu Y; Chu K; Han W; Chen Z; Tang R; Yin W; Chen X; Hu Y; Liu X; Jiang C; Li J; Yang M; Song Y; Wang X; Gao Q; Zhu F
Lancet Infect Dis; 2021 Feb; 21(2):181-192. PubMed ID: 33217362
[TBL] [Abstract][Full Text] [Related]
26. Hybrid immunity to SARS-CoV-2 in patients with chronic lymphocytic leukemia.
Mellinghoff SC; Robrecht S; Sprute R; Mayer L; Weskamm LM; Dahlke C; Gruell H; Teipel F; Schlößer HA; Siepmann K; Thelen M; Fink AM; Fischer K; Klein F; Addo MM; Kolovou A; Cornely OA; Eichhorst B; Hallek M; Langerbeins P
Eur J Haematol; 2024 May; 112(5):788-793. PubMed ID: 38311570
[TBL] [Abstract][Full Text] [Related]
27. Cellular and humoral response to the fourth BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL.
Benjamini O; Gershon R; Bar-Haim E; Lustig Y; Cohen H; Doolman R; Kedmi M; Ribakovsky E; Kneller A; Hod T; Erez N; Levy I; Rahav G; Avigdor A
Eur J Haematol; 2023 Jan; 110(1):99-108. PubMed ID: 36208015
[TBL] [Abstract][Full Text] [Related]
28. [Factors Affecting Side Effects, Seroconversion Rates and Antibody Response After Inactivated SARS-CoV-2 Vaccination in Healthcare Workers].
Şenol Akar Ş; Akçalı S; Özkaya Y; Gezginci FM; Cengiz Özyurt B; Deniz G; Karadağ Yalçın F; Özer D; Dündar Erbay P; Eser E
Mikrobiyol Bul; 2021 Oct; 55(4):519-538. PubMed ID: 34666653
[TBL] [Abstract][Full Text] [Related]
29. Safety and immunogenicity of a protein subunit COVID-19 vaccine (ZF2001) in healthy children and adolescents aged 3-17 years in China: a randomised, double-blind, placebo-controlled, phase 1 trial and an open-label, non-randomised, non-inferiority, phase 2 trial.
Gao L; Li Y; He P; Chen Z; Yang H; Li F; Zhang S; Wang D; Wang G; Yang S; Gong L; Ding F; Ling M; Wang X; Ci L; Dai L; Gao GF; Huang T; Hu Z; Ying Z; Sun J; Zuo X
Lancet Child Adolesc Health; 2023 Apr; 7(4):269-279. PubMed ID: 36803632
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia.
Herishanu Y; Avivi I; Aharon A; Shefer G; Levi S; Bronstein Y; Morales M; Ziv T; Shorer Arbel Y; Scarfò L; Joffe E; Perry C; Ghia P
Blood; 2021 Jun; 137(23):3165-3173. PubMed ID: 33861303
[TBL] [Abstract][Full Text] [Related]
31. Immune cell kinetics and antibody response in COVID-19 patients with low-count monoclonal B-cell lymphocytosis.
Oliva-Ariza G; Fuentes-Herrero B; Lecrevisse Q; Carbonell C; Pérez-Pons A; Torres-Valle A; Pozo J; Martín-Oterino JÁ; González-López Ó; López-Bernús A; Bernal-Ribes M; Belhassen-García M; Pérez-Escurza O; Pérez-Andrés M; Vazquez L; Hernández-Pérez G; García Palomo FJ; Leoz P; Costa-Alba P; Pérez-Losada E; Yeguas A; Santos Sánchez M; García-Blázquez M; Morán-Plata FJ; Damasceno D; Botafogo V; Muñoz-García N; Fluxa R; van Dongen JJM; Marcos M; Almeida J; Orfao A;
Am J Hematol; 2023 Dec; 98(12):1909-1922. PubMed ID: 37792579
[TBL] [Abstract][Full Text] [Related]
32. [Humoral Immune Response in Inactivated SARS-CoV-2 Vaccine: When Should a Booster Dose be Administered?].
Kara E; Tanır F; Demirhindi H; Mete B; Kibar F; Çetiner S; Candevir A; İnaltekin A
Mikrobiyol Bul; 2022 Jul; 56(3):566-573. PubMed ID: 35960246
[TBL] [Abstract][Full Text] [Related]
33. Generation of neutralizing antibodies against Omicron, Gamma and Delta SARS-CoV-2 variants following CoronaVac vaccination.
Silva ARD; Villas-Boas LS; Tozetto-Mendoza TR; Honorato L; Paula A; Witkin SS; Mendes-Correa MC
Rev Inst Med Trop Sao Paulo; 2022; 64():e19. PubMed ID: 35239863
[TBL] [Abstract][Full Text] [Related]
34. Anti-SARS-CoV-2 antibody response after 2 and 3 doses of BNT162b2 mRNA vaccine in patients with lymphoid malignancies.
Gressens SB; Fourati S; Le Bouter A; Le Bras F; Dupuis J; Hammoud M; El Gnaoui T; Gounot R; Roulin L; Belhadj K; Haioun C; Gallien S; Melica G; Lemonnier F
Clin Microbiol Infect; 2022 Jun; 28(6):885.e7-885.e11. PubMed ID: 35259530
[TBL] [Abstract][Full Text] [Related]
35. Antibody responses after two doses of SARS-CoV-2 mRNA-1273 vaccine in an individual with history of COVID-19 re-infection.
Inada M; Ishikane M; Terada M; Matsunaga A; Maeda K; Iwamoto N; Ujiie M; Kutsuna S; Morioka S; Ishizaka Y; Mitsuya H; Ohmagari N
Int J Infect Dis; 2022 Jun; 119():18-20. PubMed ID: 35306204
[TBL] [Abstract][Full Text] [Related]
36. Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial.
Bergman P; Blennow O; Hansson L; Mielke S; Nowak P; Chen P; Söderdahl G; Österborg A; Smith CIE; Wullimann D; Vesterbacka J; Lindgren G; Blixt L; Friman G; Wahren-Borgström E; Nordlander A; Gomez AC; Akber M; Valentini D; Norlin AC; Thalme A; Bogdanovic G; Muschiol S; Nilsson P; Hober S; Loré K; Chen MS; Buggert M; Ljunggren HG; Ljungman P; Aleman S;
EBioMedicine; 2021 Dec; 74():103705. PubMed ID: 34861491
[TBL] [Abstract][Full Text] [Related]
37. Immunogenicity and immune-persistence of the CoronaVac or Covilo inactivated COVID-19 Vaccine: a 6-month population-based cohort study.
Hua Q; Zhang H; Yao P; Xu N; Sun Y; Lu H; Xu F; Liao Y; Yang J; Mao H; Zhang Y; Zhu H; Hu X; Lv H; Jiang J
Front Immunol; 2022; 13():939311. PubMed ID: 36032136
[TBL] [Abstract][Full Text] [Related]
38. Immune correlates of protection by vaccine against SARS-CoV-2 in patients with chronic lymphocytic leukaemia.
Sorcini D; De Falco F; Gargaro M; Bozza S; Guarente V; Cardinali V; Stella A; Adamo FM; Silva Barcelos EC; Rompietti C; Dorillo E; Geraci C; Esposito A; Arcaleni R; Capoccia S; Mameli MG; Graziani A; Moretti L; Cipiciani A; Riccardi C; Mencacci A; Fallarino F; Rosati E; Sportoletti P
Br J Haematol; 2023 Apr; 201(1):45-57. PubMed ID: 36484163
[TBL] [Abstract][Full Text] [Related]
39. Quantitative Analysis of SARS-CoV-2 Antibody Levels in Cancer Patients Post Three Doses of Immunization and Prior to Breakthrough COVID-19 Infections.
Macrae K; Martinez-Cajas J; Bessai K; Abdulhamed A; Gong Y
Curr Oncol; 2022 Sep; 29(10):7059-7071. PubMed ID: 36290831
[TBL] [Abstract][Full Text] [Related]
40. Immunogenicity of a fractional or full third dose of AZD1222 vaccine or BNT162b2 messenger RNA vaccine after two doses of CoronaVac vaccines against the Delta and Omicron variants.
Niyomnaitham S; Jongkaewwattana A; Meesing A; Pinpathomrat N; Nanthapisal S; Hirankarn N; Siwamogsatham S; Kirdlarp S; Chaiwarith R; Lawpoolsri S; Phanthanawiboon S; Thitithanyanont A; Hansasuta P; Chaiyaroj S; Pitisuttithum P
Int J Infect Dis; 2023 Apr; 129():19-31. PubMed ID: 36682680
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]